Exhibit 5.1
17 July 2019
Autolus Therapeutics plc
Forest House
58 Wood Lane
London W12 7RZ
United Kingdom
Re: | Autolus Therapeutics plc — Registration Statement onForm F-3 — Exhibit 5.1 |
Ladies and Gentlemen,
We have acted as English legal advisers to Autolus Therapeutics plc, a public limited company incorporated in England and Wales (the “Company”), in connection with the preparation and filing on the date hereof with the U.S. Securities and Exchange Commission (the “SEC”) of a registration statement on FormF-3 (the “Registration Statement”), including a base prospectus (the “Base Prospectus”), which provides that it will be supplemented by one or more prospectus supplements (each such prospectus supplement, together with the Base Prospectus, a “Prospectus”), pursuant to the U.S. Securities Act of 1933, as amended (the “SecuritiesAct”).
The Registration Statement relates to the registration for the issue and sale by the Company of (i) ordinary shares at a nominal value of $0.000042 per share (“OrdinaryShares”), including Ordinary Shares in the form of American Depositary Shares (the “ADSs” and together with the Ordinary Shares, the “Shares”), (b) debt securities (“Debt Securities”) and/or (c) warrants (“Warrants”) for the purchase of Shares and/or Debt Securities in one or more series (the Shares, Debt Securities and Warrants, together, the “Securities”), in each case to the public in a registered offering or offerings, with the aggregate offering price of up to $300,000,000.
In connection with the preparation and filing of the Registration Statement, to which this letter is attached as an exhibit, with the SEC pursuant to the Securities Act, we have been asked to provide this letter and opinions on certain matters, as set out below. No opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related applicable Prospectus, other than as expressly stated herein with respect to the issue of the Securities. We have taken instruction in this regard solely from the Company.
1.2 | Defined terms and headings |
In this letter:
| (a) | capitalised terms used without definition in this letter or the schedules hereto have the meanings assigned to them in the Registration Statement unless a contrary indication appears; |
| (b) | headings are for ease of reference only and shall not affect interpretation; and |
| (c) | the term “Shares” shall include any additional ADSs registered by the Company pursuant to Rule 462(b) under the Securities Act in connection with the registered offering or offerings contemplated by the Registration Statement. |